Sou Hu Cai Jing·2025-05-14 05:11Core Viewpoint - The pharmaceutical market, particularly innovative drug companies, is experiencing significant growth, with substantial support from policies, leading to the emergence of high-performing stocks similar to Changchun Gaoxin. Group 1: Market Performance - The Hong Kong innovative drug index has increased from 859 points at the beginning of the year to 1284 points, representing a 50% rise [1] - The mainland innovative drug index has risen from a low of 948 to a high of 1156, showing a 22% increase, indicating a significant lag compared to Hong Kong [1] Group 2: Stock Performance - Several stocks in the Hong Kong innovative drug sector have seen substantial gains, such as: - Kintor Pharmaceutical rising from 2.48 to 19.78 HKD - Akeso increasing from 1.2 to 4.3 HKD - CanSino Biologics moving from 2 to 8.73 HKD - CStone Pharmaceuticals growing from 0.8 to 3.89 HKD - Innovent Biologics increasing from 26.45 to 105.5 HKD [4] - The current bullish trend in Hong Kong's innovative drug sector is viewed as just the beginning, with expectations of a long-term market cycle lasting 50 years [4] Group 3: Historical Comparisons - Historical data from 2005 to 2007 shows that Hong Kong real estate stocks typically initiated their upward trends over six months before A-share stocks, with A-share stocks generally experiencing greater increases [5] - Examples include: - China Overseas Land rising from 2.29 to 21.95 HKD - Vanke increasing from 6.76 to 33.82 HKD - Deep Zhenye rising from 19.90 to 271.8 HKD [5] - The patterns observed in the real estate sector may provide insights into the potential trajectory of mainland innovative drug stocks, suggesting a possible follow-up to the Hong Kong market's performance [5]